This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/pubchem-substance/
n20http://www.rxlist.com/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/kegg-drug/
n17http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/chebi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB04865/identifier/wikipedia/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04865
rdf:type
n5:Drug
n5:description
Homoharringtonine, AKA HHT or omacetaxine mepesuccinate, is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Homoharringtonine is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, homoharringtonine received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, homoharringtonine received Orphan Drug status from the FDA for the treatment of CML. In November 2006, homoharringtonine, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, homoharringtonine was marketed under the brand name Synribo™ and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
n5:dosage
n18:271B5B05-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Lou YJ, Qian WB, Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007 Jul;48(7):1400-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17613769 # Jie H, Donghua H, Xingkui X, Liang G, Wenjun W, Xiaoyan H, Zhen C: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma. 2007 May;48(5):964-77. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17487741 # FDA label.
n5:group
approved
n5:halfLife
Homoharringtonine has a half life of about 6 hours after subcutaneous administration.
n5:indication
Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
owl:sameAs
n17:DB04865
dcterms:title
Homoharringtonine
adms:identifier
n4:63459-177-14 n6:72332 n8:DB04865 n9:D08956 n10:71019 n11:65276 n21:11075063 n22:Omacetaxine_mepesuccinate
n5:mechanismOfAction
Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.
n5:routeOfElimination
The main route of elimination for homoharringtonine is still unknown, but renal elimination is less than 15%.
n5:synonym
Cephalotaxus alkaloid omacetaxine mepesuccinate CGX-635 Myelostat HHT
n5:toxicity
The most severe adverse effects after homoharringtonine administration are myelosuppression, bleeding, hyperglycemia, and fetal harm.
n5:volumeOfDistribution
Homoharringtonine has a steady state Vd of 141 ± 93.4 L.
n5:foodInteraction
Homoharringtonine is administered subcutaneously, so food should have no effects.
n5:proteinBinding
Plasma protein binding is equal or less than 50%.
n5:synthesisReference
Yaguang Liu, "Process for producing harringtonine and homoharringtonine." U.S. Patent US4783454, issued June, 1980.
foaf:page
n13:omacetaxine-injection.html n20:synribo-drug.htm
n5:IUPAC-Name
n7:271B5B0A-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B5B10-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B5B0F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B5B0C-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B5B0D-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B5B0E-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B5B08-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B5B06-363D-11E5-9242-09173F13E4C5 n7:271B5B09-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B5B07-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:L01XX40
n5:H-Bond-Acceptor-Count
n7:271B5B16-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B5B17-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B5B11-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B5B12-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B5B14-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B5B13-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B5B15-363D-11E5-9242-09173F13E4C5
n5:absorption
Homoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
26833-87-4
n5:category
n5:clearance
Clearance for homoharringtonine was not quantified.
n5:Bioavailability
n7:271B5B1C-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B5B1E-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B5B1F-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B5B1B-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B5B1A-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B5B1D-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B5B0B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B5B18-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B5B19-363D-11E5-9242-09173F13E4C5